[2] It is produced and marketed by Warner Chilcott, Sanofi-Aventis, and in Japan by Takeda under the trade names Actonel, Atelvia, and Benet.

[4] The manufacturers of Boniva, a rival bisphosphonate, were accused in the suit of causing a "serious public health risk" through misrepresentation of scientific findings.

In a ruling on September 7, 2006, U.S. District Judge Paul A. Crotty rejected P&G's attempted injunction.

[5] In 2006, P&G faced controversy over its handling of clinical research involving risedronate (News Reports[6] and discussion).

[7] In common with other bisphosphonate drugs, risedronate appears to be associated with the rare side effect osteonecrosis of the jaw, often preceded by dental procedures inducing trauma to the bone.